Development of a stable liquid formulation of live attenuated influenza vaccine

Highlights • Multiple excipients were screened for their ability to stabilize influenza vaccine. • Identified a liquid formulation with storage stability for one year at 2–8 °C. • A stable liquid formulation may lead to wider use of influenza vaccination.

Saved in:
Bibliographic Details
Published inVaccine Vol. 34; no. 32; pp. 3676 - 3683
Main Authors White, Jessica A, Estrada, Marcus, Flood, E. Alexander, Mahmood, Kutub, Dhere, Rajeev, Chen, Dexiang
Format Journal Article
LanguageEnglish
Published Netherlands Elsevier Ltd 12.07.2016
Elsevier Limited
Elsevier Science
Subjects
Allergy and Immunology
Animals
Confidence intervals
Developing countries
Distribution costs
Dogs
Drug Stability
Excipients - chemistry
Genomes
Influenza
Influenza A Virus, H1N1 Subtype
Influenza B virus
Influenza vaccine
Influenza Vaccines - chemistry
Influenza virus
LDCs
Licenses
Madin Darby Canine Kidney Cells
Manufacturers
Orthomyxoviridae
Pandemics
Seasons
Vaccine stabilization
Vaccines
Vaccines, Attenuated - chemistry
Viruses
INE, USA, California
Australia, Queensland, Brisbane
Vaccine stabilization
Influenza vaccine
Online AccessGet full text

Cover

More Information
Summary:Highlights • Multiple excipients were screened for their ability to stabilize influenza vaccine. • Identified a liquid formulation with storage stability for one year at 2–8 °C. • A stable liquid formulation may lead to wider use of influenza vaccination.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:0264-410X
1873-2518
DOI:10.1016/j.vaccine.2016.04.074